tbuckley/cabot-search huggingface dataset:
Complications tardives de la sphinctérotomie endoscopique (SE) pour lithiase de la voie biliaire principale (LVBP) chez 190 patients cholécystectomisés-étude prospective
Authors: PH Desurmont, PH Bulois, PH Houcke, V Maunoury, JC Paris
Journal: Endoscopy (2004)

But: Les conséquences à long terme de la SE restent mal connues, les principales études étant souvent rétrospectives, chez des patients non-cholécystectomisés. Le but de ce travail est de préciser les caractéristiques et la fréquence des complications tardives de la SE. Patients et Méthodes: Cent quatre vingt dix patients successifs, 131 femmes (69%), 59 hommes (31%), âge moyen: 57,5 ans ± 15, sphinctérotomisés pour LVBP ont été inclus du 1er février 1995 au 1er février 2000 ; 85 patients (45%) étaient cholécystectomisés lors de la SE, 105 (55%) l’ont été 1 à 4 mois après. Quatre patients ont été perdus de vue et le suivi à 3 mois, puis annuel était effectué par courrier aux patients et/ou contact avec le médecin traitant, avec un recul moyen de 5 ans et 2 mois. Résultats: 1) Un patient diabétique et cirrhotique a eu un abcès du foie 28 mois après la SE (guéri médicalement). 2) Neuf patients (4,8%) ont présenté une récidive d’angiocholite en moyenne 31 mois après la SE (extrêmes: 13 à 59 mois), 6 fois/9 avec récidive de LVBP, 3 fois/9 sans calcul; Une sténose de la SE n’a été suspectée que 2 fois/9, une mauvaise vidange cholédocienne sans obstacle avec SE perméable 7 fois/9; Le traitement a été endoscopique (extraction de calculs, lavage du cholédoque, nouvelle SE si sténose) (n = 6), médical (sels biliaire ± antibiotiques) (n = 2), chirurgical (anastomose bilio-digestive) (n = 1). Six des 9 patients ont néanmoins eu plusieurs récidives et l’un d’entre eux est décédé 25 mois après la SE d’une septicémie d’origine biliaire probable. 3) Dix-huit autres patients sont décédés en moyenne 36 mois après la SE (extrêmes 1 à 69 mois): 11 accidents cardio-vasculaires ou cérébraux, 6 cancers (sein, rein, poumon, ésophage) et 1 suicide. Conclusion: 1) La fréquence des angiocholites récidivantes dans les 5 ans qui suivent une SE pour LVBP chez des patients cholécystectomisés est de 4,8% avec une mortalité de 0,5%. 2) Leur étiologie est incertaine mais les sténoses de la SE sont très rares et des troubles de l’évacuation biliaire semblent plutôt être en cause. 3) Le traitement de ces récidives est médical et endoscopique et le recours à la chirurgieexceptionnel.
Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes
Authors: Julie Schanz, Heinz Tüchler, Francesc Sole, Guillermo Sanz, Guillermo Garcia-Manero, Michelle M. Le Beau, John M. Bennett, Marilyn L. Slovak, Pierre Fenaux, Luca Malcovati, Mario Cazzola, Peter Valent, Kazuma Ohyashiki, Alessandro Levis, Mikkael A. Sekeres, Sudhir Tauro, Silvia Magalhaes, A. A van de Loosdrecht, Jaroslav Cermak, Michael Luebbert, Reinhard Stauder, Eva Hellstrom-Lindberg, Tatjana Gindina, Ulrich Germing, Peter Greenberg, Detlef Haase
Journal: Blood (2015)
Population Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody, Siltuximab (CNTO 328), in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Authors: Lanyi Xie, Lilian Y Li, Razelle Kurzrock, Frits van Rhee, Xiang Qin, Manjula Reddy, Ming Qi, Hugh M Davis, Honghui Zhou, Thomas A Puchalski
Journal: Blood (2012)
Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases.
Authors: Edward D. Agura, R. Brian Berryman, Joseph W. Fay, Luis A. Pineiro, Estil A. Vance, Mirjana Tadic-Ovcina
Journal: Blood (2007)
Integrated molecular pathology analysis of fine needle aspiration biopsy specimens for tumor diagnosis and characterization
Authors: A. Radfar, S. D. Finkelstein, P. A. Finkelstein, M. M. Wilson, V. G. Vogel
Journal: Journal of Clinical Oncology (2005)

9529 Background: Fine needle aspiration biopsy (FNAB) is increasingly used to arrive at cancer diagnosis. It can be limited by low specificity and sensitivity with high indeterminate rate. Pathologists may differ in general acceptance based on lack of clearcut microscopic diagnostic criteria. Incorporating mutational analysis into FNAP evaluation offers the potential to improve diagnostic accuracy and provide valuable prognostic information. We report a novel integrated molecular pathology approach for clinical FNAP diagnosis. Methods: Residual FNAB material was collected ex vivo from 17 patients with solid organ cancers (lung [4], esophagus [3], stomach [1], colon [4], breast [2], kidney [2] and soft tissue [1]). Corresponding tissue sections of the resected organ were gathered for correlative mutational profiling. Three types of representative FNAB samples were obtained consisting of 1) 10–25 ul of original FNAB cellular fluid {OCF}, 2) 15–30 mls of residual liquid based cytology fluid {LCF} and 3) microdissected individual cell clusters from cytology slides {MCC}. The DNA from each sample was extracted and PCR amplified for a broad panel of markers targeting 1p,3p,5q,9p,10q,17p, and k-ras-2. Cumulative amount of LOH and point mutational change was determined as well as timeline of mutation acquisition for each sample using high through-put electrophoresis. Results: A total of 221 individual genotyping reactions were performed resulting in 155 informative results and 83 detectable mutations. The range of concordance rate for mutational change was OCF: 76- 92%, LCF: 83- 94%, MCC: 74- 92%, all three methods: 91- 99%. The time course of mutation acquisition could be established by each method and was similar to that defined in resected tissue in all cases. Molecular analysis did not interfere with traditional cytology practice for evaluating these specimens. Conclusions: Integrated mutational analysis performed before, during and following cytology evaluation, using residual samples can provide highly discriminating information to diagnose, classify and prognosticate cancer and related lesions while complementing pathology practice. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration RedPath Integrated Pathology RedPath Integrated Pathology RedPath Integrated Pathology
Evaluation of an Automated Ficoll Procedure To Enrich for Mononuclear Cells for Use in Clinical Trials.
Authors: Carmen A. Sepulveda, Sara J. Richman, Indreshpal Kaur, Anna Shen, Sangeeta Khorana, Sean L. O’Connor, Richard E. Champlin, Elizabeth J. Shpall, John D. McMannis
Journal: Blood (2007)
SP0165 Balneotherapy:Efficacy and Safety in Osteoarthritis
Authors: T. Bender
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The scientific field dealing with balneotherapy is called balneology.Balneotherapy means the use of natural mineral waters, natural peloids and muds, natural sources of different gases for medical purposes. <h3>Objectives</h3> A growing number of evidence is available about the beneficial effect of balneotherapy for patients suffering from Osteoarthritis. The lecture would like to give a survey about the efficacy and safety of balneotherapy in Osteoarthritis <h3>Methods</h3> We searched in the medical database (Pubmed, Scopus, Pedro, Web of Sciences, Sciences Direct) and took into consideration articles only published in the English language. We focused on the clinical studies, but we paid attention on the possible side effects,risks and harmful effects of balneotherapy. We overviewed not only the RTC studies, but also the reviews,meteaanalysis and guidelines. <h3>Results</h3> Untill now more than 50 RTC single or double blind studies had been published on the effect of balneotherapy in OA(this number continually increased).The majorities of the studies dealing with the role of the balneotherapy on the knee arthrosis, but there are studies involved with the shoulder,neck,hand,hip and lumbar regions too. On the basis of the available evidence, balneotherapy has a beneficial effect on pain and quality of life for OA patients. As for as the safety of balneotherapy,the side effects during the treatment are negligible. On account of the latest OARSI guideline, balneotherapy is an appropriate treatment in case of multi- joint type OA with comorbidities. <h3>Conclusion</h3> On the basis of the available evidence balneotherapy is effective and safe, non-pharmacological therapy in the treatment of OA, but further multicentric studies are necesseray to prove its efficacy. <h3>References</h3> Bender T, Karagülle Z, Bálint GP, Gutenbrunner C, Bálint PV, Sukenik S Hydrotherapy, balneotherapy, and spa treatment in pain management.Rheumatol Int. 2005 Apr;25(3):220–4. Forestier R, Desfour H, Tessier JM, Françon A, Foote AM, Genty C, Rolland C, Roques CF, Bosson JL.Ann Rheum Dis. Spa therapy in the treatment of knee osteoarthritis: a large randomised multicentre trial.2010 Apr;69(4):660–5. Bender T, Bálint G, Prohászka Z, Géher P, Tefner IK. Evidence-based hydro- and balneotherapy in Hungary – a systematic review and meta-analysis.Int J Biometeorol. 2014 Apr;58(3):311–23. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M. OARSI guidelines for the non-surgical management of knee osteoarthritis.Osteoarthritis Cartilage. 2014 Mar;22(3):363–88. <h3>Disclosure of Interest</h3> None declared
Long-Term Outcomes of TBI-Based Myeloablative SCT In 292 Consecutive Adults with Ph-Negative ALL: Similar Outcomes for Transplantation Using Related Donor, Well-Matched Unrelated Donor, or Partially Matched Unrelated Donor Sources
Authors: Seok Lee, Seung-Ah Yahng, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park
Journal: Blood (2010)
Prenatal alcohol exposure and pregnancy and childhood outcomes: a systematic review of alternative analytical approaches
Authors: Loubaba Mamluk, Hannah B Edwards, Jelena Savović, Verity Leach, Timothy Jones, Theresa H M Moore, Sarah J Lewis, Jenny L Donovan, Deborah A Lawlor, George Davey Smith, Abigail Fraser, Luisa Zuccolo
Journal: The Lancet (2016)
Involvement of Fatty Acid Synthase in Azacytidine-Induced Cytotoxicity in Waldenstrom's Macroglobulinemia.
Authors: Lian Xu, Christopher J Patterson, Jenny Sun, Guang Yang, Yangsheng Zhou, Zachary Hunter, Evdoxia Hatjiharissi, Bryan Ciccarelli, Ping Gong, Xia Liu, Hsiuyi Tseng, Thea Ioakimidis, Robert Manning, Christina Hanzis, Yang Cao, Megan Lewicki, Steven Treon
Journal: Blood (2009)
Re: Omar Fahmy, Mohd Ghani Khairul-Asri, Christian Schwentner, et al. Algorithm for Optimal Urethral Coverage in Hypospadias and Fistula Repair: A Systematic Review. Eur Urol 2016;70:293–8
Authors: Lei Kang, Lugang Huang, Jingti Zhang
Journal: European Urology (2016)
Evaluation of Humoral Immune Responses to Vaccination with Tetanus Toxoid and KLH in Rituximab-Treated Follicular Non-Hodgkin’s Lymphoma Patients Compared to Healthy Volunteers
Authors: M. Wayne Saville, Nancy Valente, Rachelle Perea, Kye Gilder, Judith Berlfein, Ilya Zyuzgin, David Belada, Andre Banat, Tudor Ciuleanu
Journal: Blood (2008)
SAT0606 The Comorbidity between Systemic Lupus Erythematosus and Malignancies: A Cross-Sectional Population Based Study
Authors: S. Azrielant, S. Tiosano, N. Mahroum, D. Comaneshter, A.D. Cohen, H. Amital
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Autoimmune conditions often reflect dysregulation of the immune system, which appears to be of great significance in the development of malignancies [1]. Previous studies support an association between systemic lupus erythematosus (SLE) and malignancies; however, their findings on specific malignancies are inconsistent, and their design might not represent the population of SLE patients, due to selection bias [2–4]. <h3>Objectives</h3> Our goal was to investigate the association between the presence of SLE and various malignancies, in a large-scale population-based study. <h3>Methods</h3> Data for this study was collected from the database of "Clalit Health services", the largest state-mandated health service organization in Israel. All adult members diagnosed with SLE were included (n=5,018) and their age and sex-matched controls (n=25,090), creating a cross-sectional population-based study. Medical records of all subjects were analyzed for documentation of malignancies. Logistic regression was preformed to control for age, gender, BMI, smoking and socioeconomic status. <h3>Results</h3> Diagnosis of malignancy (of any type) was more prevalent in the SLE population in comparison to controls (odds ratio [OR] 3.35, 95% confidence interval [CI] 3.02–3.72). Also, SLE diagnosis was found to be independently associated with higher proportions of non-Hodgkin lymphoma (OR 3.02, 95% CI 2.72–3.33), Hodgkin lymphoma (OR 2.43 95% CI 1.88–2.99), multiple myeloma (OR 2.57, 95% CI 1.85–3.28), cervix uteri malignancies (OR 1.65, 95% CI 1.10–2.20) and genital organ malignancies (OR 2.32 95% CI 1.42–3.22), after adjustment for confounding variables. <h3>Conclusions</h3> SLE diagnosis was found to be independently associated with higher proportions of malignancies, specifically hematologic malignancies. These findings should be considered when treating SLE patients, and possibly influence their screening routine. <h3>References</h3> de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24–37. doi:10.1038/nrc1782 Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481–90. doi:10.1002/art.21029 Sultan SM, Ioannou Y, Isenberg D a. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford) 2000;39:1147–52. Mellemkjaer L, Andersen V, Linet MS, et al. Non-Hodgkin9s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:761–8. <h3>Disclosure of Interest</h3> None declared
Non-Relapse Mortality Associated with Autologous Stem Cell Transplant (ASCT).
Authors: Christy Stotler, Matt Kalaycio, Robert M. Dean, Ronald Sobecks, Edward A. Copelan, Steven Andresen, Brad Pohlman, John William Sweetenham, Lisa Rybicki, Stacey Brown, Kim Bell, Kelly Cherni, Laura Bernhard, Christina Ferraro, Brian J. Bolwell
Journal: Blood (2007)
Circulating Concentrations of Orexin A Predict Left Ventricular Myocardial Remodeling
Authors: Nasrien E. Ibrahim, Dustin J. Rabideau, Hanna K. Gaggin, Arianna M. Belcher, Michael J. Conrad, Petr Jarolim, James L. Januzzi
Journal: Journal of the American College of Cardiology (2016)

Among pivotal processes in heart failure (HF) progression is remodeling of the myocardium, which involves progressive cardiomyocyte cell death with interstitial fibrosis. On a macroscopic level, myocardial remodeling manifests as progressive increase in left ventricular (LV) volumes and reduction in
SP0089 Osteoporosis in Juvenile Idiopathic Arthritis
Authors: R. Cimaz
Journal: Annals of the Rheumatic Diseases (2016)

In children with rheumatic disorders the physiological development of bone strength in response to mechanical loads (the mechanostat model) is frequently impaired. In this population the prolonged inflammatory process and systemic treatment with glucocorticoids (GC) represent the two main risk factors which interfere with the bone remodelling process. Up to 6% of children with GC-treated rheumatic disorders develop a vertebral fracture in the first 12 months of therapy; children with more severe inflammation and more systemic involvement, such as those with systemic-onset JIA or connective tissue diseases, appear to be at higher risk. Inflammation exerts a direct and detrimental effect on bone, as generalized bone loss can occur independently from GC exposure. Although cytokines are considered to be the final executors of chronic inflammation on bone, the role of immune cells (e.g. Th17) has recently been highlighted. GC therapy, often at high doses and for prolonged periods, is associated with detrimental effects on bone mass and growth by means of multiple pathogenic mechanisms. By exerting a direct effect on bone cells, GC-induced osteoporosis is characterized by a decreased bone turnover with a disproportionate reduction in bone formation over bone resorption. The most important clinical outcome arising from lack of bone strength development in childhood rheumatic disorders is represented by fragility fractures. In order to diagnose osteoporosis in children, fracture history should be considered the base of the definition, with additional consideration for the risk factors (sun avoidance, vitamin D deficiency, reduced physical activity), and the overall BMD Z-score trajectory. Several techniques can be used to evaluated bone health in children (e.g. Dual-energy x-ray absorptiometry, peripheral quantitative computerized tomography, and quantitative ultrasound). Dual-energy x-ray absorptiometry (DXA) is the technique currently considered the most appropriate for children because of low radiation, speed, and accuracy. In rheumatic diseases, a reduction of disease activity represent the mainstay of the treatment, and an anti-inflammatory action of medications such as methotrexate and b<i>iological</i> response <i>modifiers</i> has been associated to an improved bone health. The effect of bone-targeted therapy such as bisphosphonates on a developing skeleton has also been explored in pediatric rheumatology. In addition to correct vitamin D deficiency and encourage physical activity, oral or i.v. bisphosphonates can therefore be useful in selected patients, but caution should be used since their long-term effects on a growing skeleton are still unknown. <h3>Disclosure of Interest</h3> None declared
P0358 : Risk predictors of hepatocellular carcinoma among cirrhotic patients chronically infected with hepatitis B
Authors: J.D. Chien, J. Liu, M.-H. Lee, C.-L. Jen, R. Batrla-Utermann, S.-N. Lu, L.-Y. Wang, S.-L. You, H.-I. Yang, C.-J. Chen
Journal: Journal of Hepatology (2015)
SAT0527 Predictors of Back Pain in Middle Aged Women: Data from The Australian Longitudinal Study on Women's Health
Authors: S.R.E. Brady, S.M. Hussain, W.J. Brown, S. Heritier, Y. Wang, H. Teede, D.M. Urquhart, F.M. Cicuttini
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Back pain is a major public health issue, causing greater disability worldwide than any other condition. Given the limited treatment options available, an understanding of the predictors of back pain is vital to optimize preventive strategies. Women are not only more likely to suffer from back pain, they are also more likely to utilise health care services to a greater extent than men. However, few studies to date have examined modifiable predictors of back pain in middle-aged women, with exposure and outcome measures assessed at multiple time points and major inconsistency and knowledge gaps persist in this area. <h3>Objectives</h3> Our aim was to identify modifiable risk factors for back pain in middle-aged women. <h3>Methods</h3> Women born between 1946 and 1951 were randomly selected from the Australian national health insurance scheme database to participate in The Australian Longitudinal Study of Women9s Health. Self-reported data on back pain in the last 12 months, weight, height, age, physical activity, depression, menopause status and other socio-demographic factors were collected in 1998, 2001, 2004, 2007, 2010 and 2013. In 1998, 12,338 women completed the survey and 10,011 (74%) completed the 2013 survey 15 years later. <h3>Results</h3> At baseline, median (range) age was 49.5 (44.6 – 53.5) years and 54% reported back pain. In longitudinal multivariate analysis, baseline weight (per 5kg increments) and depression were independent predictors of back pain over each 3 year survey interval and over the following 15 year period, whereas participation in vigorous physical activity was protective. Mean weight gain over the first three years of 1.4kg was associated with an increased risk of back pain over the following 12 years (multivariate OR 1.01, 95% CI 1.01–1.02). The effects of weight on back pain were not affected by participation in vigorous physical activity, being menopausal, or depression status, but the association between weight and back pain tended to be more consistent in those who were overweight or obese. <h3>Conclusions</h3> Back pain is common in middle-aged women. Increased weight, weight gain and depression were independent predictors of back pain over 15 years, whereas participation in vigorous physical activity was protective. Targeting these lifestyle factors is an important area for future research on reducing the burden of back pain in middle-aged women. <h3>Disclosure of Interest</h3> None declared
AB0195 Bone Erosion and Bone Loss Profile in Rheumatoid Arthritis: about 93 Moroccan Patients
Authors: H. Azzouzi, O. Akkar, M. Lehraiki, L. Lehlou, L. Boutouala, L. Ichchou
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is a known cause of joint destruction and systemic bone loss. It is now clear that the management of inflammation in RA is the key to a better control of articular damage and osteoporosis. However, systemic inflammation is not the only determinant of bone damage. <h3>Objectives</h3> The aim of the present work is to evaluate the bone erosion and bone loss profile in RA patients. <h3>Methods</h3> Ninety-three patients have been identified meeting the ACR EULAR criteria of RA. We have collected data about age, smoking, alcoholism, steroid prescription, body mass index (BMI), disease duration and activity (DAS28), functional disability (HAQ) and bone mineral density (BMD) measured with DXA. Bone erosion was calculated by the Sharp Van Der Heijde score. Data analysis was carried out using the SPSS 20 Software. p&lt;0.05 was considered statistically significant. <h3>Results</h3> The mean±SD age was 51.59±12.38 years and the mean±SD disease duration 12.07±9.19 years. The mean±SD sharp score was 70.33±48.93 and 36.6% of patients had osteoporosis. The median RA diagnosis lag time was 24 months [12–72] after onset of symptoms. Bone mineral density in the femoral neck was significantly associated with Sharp score (p=0.000) and age (p=0.004), HAQ (p=0.003), disease duration (p=0.000), steroid intake (p=0.035), spine BMD (p=0.000) and BMI (p=0.044). Adjusted to age, spine BMD and BMI, femoral neck BMD (p=0.04) was an associated factor of bone damage (OR: - 0.442, 95% CI -240.24 to -19.51). <h3>Conclusions</h3> Delayed diagnosis has led to greater bone damage in our RA population. Consequently, more efforts should be done to shorten this period in order to improve the disease control and the patients9 quality of life. <h3>Disclosure of Interest</h3> None declared
心肺复苏的国际新标准 指南推荐胸部按压／通气比为30：2
Authors: 王琳（译）
Journal: BMJ (2006)

有关心肺复苏的权威性国际新指南已于近日发表。指南由国际复苏联络委员会（International Liaison Committee on Resuscitation）协调，通过全球协作产生。该委员会成立于1992年，于2000年制定了第一个国际性指南。2005年的新指南被认为是“科学共识”，反映了人们逐渐认识到不同国家和地区有着不同的资源与需求。
NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience
Authors: Virginie Chesnais, Aline Renneville, Andrea Toma, Veronique Sardnal, Marie Passet, Audrey Gauthier, Jacques Delaunay, Aspasia Stamatoulas, Odile Beyne-Rauzy, Pierre Fenaux, Francois Dreyfus, Claude Preudhomme, Olivier Kosmider, Michaela Fontenay
Journal: Blood (2014)
The computer is still in training
Authors: Pablo Millares Martin
Journal: BMJ (2016)

The article about Google’s artificial intelligence (AI) company, DeepMind1 raises two issues—the use of AI itself and the access to data.

Regarding AI, the presumption is it will run before it can walk. No doubt medicine is more complex now than a century ago and will be even more so in a couple of decades. Doctors cannot keep up to date with the vast …